Current treatments for oropharyngeal squamous cell carcinoma and the move towards molecular therapy.

IF 2.8 4区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of Pharmacy and Pharmacology Pub Date : 2024-08-13 DOI:10.1093/jpp/rgae107

Mitra Elmi, Joshua H Dass, Crispin R Dass

{"title":"Current treatments for oropharyngeal squamous cell carcinoma and the move towards molecular therapy.","authors":"Mitra Elmi, Joshua H Dass, Crispin R Dass","doi":"10.1093/jpp/rgae107","DOIUrl":null,"url":null,"abstract":"Objectives: In this review, we discuss oropharyngeal squamous cell carcinoma (OPSCC) treatment options with a focus on the molecular mechanisms of OPSCC in head and neck squamous cell carcinoma (HNSCC) and head and neck cancers (HNCs). Treatment can be radical intent (aim for cure) or palliative intent (aim for disease control and symptom management). OPSCC is a prominent subset of HNSCCs in Australia and the Western World.Method: We looked at the current conventional treatment options with an overview of recent advances and future endeavours.Key findings: We identified that radiotherapy is the primary management for OPSCC in most countries, including the USA, UK, NZ, and Australia. In contrast, surgery is only considered for superficial OPSCC or neck surgery. If surgery is incomplete, then definitive management still requires radiotherapy.Conclusion: Molecular therapy is largely at the preclinical stage, with cetuximab, nivolumab, pembrolizumab, Lenvatinib, and bevacizumab being tested clinically currently.","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy and Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jpp/rgae107","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: In this review, we discuss oropharyngeal squamous cell carcinoma (OPSCC) treatment options with a focus on the molecular mechanisms of OPSCC in head and neck squamous cell carcinoma (HNSCC) and head and neck cancers (HNCs). Treatment can be radical intent (aim for cure) or palliative intent (aim for disease control and symptom management). OPSCC is a prominent subset of HNSCCs in Australia and the Western World.

Method: We looked at the current conventional treatment options with an overview of recent advances and future endeavours.

Key findings: We identified that radiotherapy is the primary management for OPSCC in most countries, including the USA, UK, NZ, and Australia. In contrast, surgery is only considered for superficial OPSCC or neck surgery. If surgery is incomplete, then definitive management still requires radiotherapy.

Conclusion: Molecular therapy is largely at the preclinical stage, with cetuximab, nivolumab, pembrolizumab, Lenvatinib, and bevacizumab being tested clinically currently.

查看原文本刊更多论文

口咽鳞状细胞癌的现有治疗方法以及分子疗法的发展。

目的：在这篇综述中，我们将讨论口咽鳞状细胞癌（OPSCC）的治疗方案，重点关注头颈部鳞状细胞癌（HNSCC）和头颈部癌症（HNCs）中口咽鳞状细胞癌的分子机制。治疗可以是根治性的（以治愈为目的），也可以是姑息性的（以控制疾病和控制症状为目的）。在澳大利亚和西方国家，OPSCC是HNSCC的一个重要分支：我们研究了当前的常规治疗方案，并概述了近期的进展和未来的努力：我们发现，在大多数国家，包括美国、英国、新西兰和澳大利亚，放疗是治疗 OPSCC 的主要方法。相比之下，只有浅表 OPSCC 或颈部手术才会考虑手术治疗。如果手术不彻底，那么最终治疗仍然需要放疗：结论：分子疗法目前主要处于临床前阶段，西妥昔单抗、nivolumab、pembrolizumab、Lenvatinib和贝伐珠单抗目前正在接受临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pharmacy and Pharmacology 医学-药学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： JPP keeps pace with new research on how drug action may be optimized by new technologies, and attention is given to understanding and improving drug interactions in the body. At the same time, the journal maintains its established and well-respected core strengths in areas such as pharmaceutics and drug delivery, experimental and clinical pharmacology, biopharmaceutics and drug disposition, and drugs from natural sources. JPP publishes at least one special issue on a topical theme each year.